首页> 外文OA文献 >The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma

【2h】

The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma

机译：PI3K / mTOR双抑制剂NVP-BEZ235降低了卵巢透明细胞癌的生长

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
TETSURO OISHI; HIROAKI ITAMOCHI; AKIKO KUDOH; MICHIKO NONAKA; MISAKI KATO; MAYUMI NISHIMURA; NAO OUMI; SEIYA SATO; JUN NANIWA; SHINYA SATO; MUNEAKI SHIMADA; JUNZO KIGAWA; TASUKU HARADA;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma [J] . Oishi Tetsuro, Itamochi Hiroaki, Kudoh Akiko, Oncology reports . 2014,第2期

机译：PI3K / mTOR双重抑制剂NVP-BEZ235降低卵巢透明细胞癌的生长
2. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models [J] . Schrauwen Stefanie, Depreeuw Jeroen, Coenegrachts Lieve, Gynecologic Oncology: An International Journal . 2015,第1期

机译：PI3K / AKT / mTOR（NVP-BEZ235）和Ras / Raf / MEK（AZD6244）通路的双重阻滞协同抑制原发性子宫内膜样子宫内膜癌培养物的生长，而NVP-BEZ235减少相应异种移植模型中的肿瘤生长
3. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced [J] . JebahiA., VilledieuM., Pétigny-LechartierC., Cancer letters . 2014,第1a2期

机译：PI3K / mTOR双重抑制剂NVP-BEZ235降低Mcl-1表达并使卵巢癌细胞对Bcl-xL靶向策略敏感，前提是诱导Bim表达
4. Combination of PI3K/Akt/mTOR inhibitors and PDT in endothelial and tumor cells. [C] . Fateye, Babasola, Chen Bin Optical methods for tumor treatment and detection: mechanisms and techniques in photodynamic therapy XX . 2011

机译：内皮细胞和肿瘤细胞中PI3K / Akt / mTOR抑制剂和PDT的组合。
5. Clinical Pharmacokinetics of the Novel Combination of BEZ235, PI3K/mTOR Inhibitor, and Everolimus, mTOR Inhibitor: Phase I Clinical Studies and Non-Clinical Mechanistic Assessment [D] . Moorthy, Ganesh P. 2015

机译：BEZ235，PI3K / mTOR抑制剂和依维莫司，mTOR抑制剂的新型组合的临床药代动力学：I期临床研究和非临床机制评估
6. Genotype-Dependent Efficacy of a Dual PI3K/mTOR Inhibitor, NVP-BEZ235, and an mTOR Inhibitor, RAD001, in Endometrial Carcinomas [O] . Keiko Shoji, Katsutoshi Oda, Tomoko Kashiyama, 2009

机译：子宫内膜癌中双重PI3K / mTOR抑制剂NVP-BEZ235和mTOR抑制剂RAD001的基因型依赖性疗效
7. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models [O] . Schrauwen Stefanie, Depreeuw Jeroen, Coenegrachts Lieve, 2015

机译：PI3K / AKT / mTOR（NVP-BEZ235）和Ras / Raf / MEK（AZD6244）通路的双重阻滞协同抑制原发性子宫内膜样子宫内膜癌培养物的生长，而NVP-BEZ235降低相应异种移植模型中的肿瘤生长

The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma

著录项

引文网络

相似文献

相关主题

期刊订阅